Byetta vs Saxenda

Drug comparison

Last updated 2026-05-28 15:46 UTC

Byetta (exenatide by AstraZeneca) is a once-daily injection for type 2 diabetes, while Saxenda (liraglutide by Novo Nordisk) is a once-daily injection approved for weight management in obesity. Both are given as subcutaneous shots, but Byetta targets blood sugar control in diabetes, whereas Saxenda is used for chronic weight loss in people with obesity.

AI summary of the sources below.

	Byetta	Saxenda
Active ingredient	exenatide	liraglutide
Manufacturer	astrazeneca	novo-nordisk
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	obesity
Label updated	2025-09-02	2026-02-25

Compare full details on the Byetta and Saxenda pages.